After two successful vaccinations, the “Vaccination Center” has been decided to start vaccination action nationwide on January 16, after future festivals, including Lohri, Makar Sankranti, Pongal, Magh Bihu, etc., government sources said on Saturday. The decision came after the prime minister held a high-level review meeting with the cabinet secretary, prime minister’s chief secretary, health secretary and other senior officials to review COVID-19 status in the country, along with state readiness. / UT for COVID vaccination. The Prime Minister will interact with all the CMs on Monday in the same way.
The army takes the Chinese soldier into custody after he moved to the Indian side of the LAC
Launch of the vaccine on January 16
Priority will be given to health workers and front-line workers, estimated at about 3 million, who are currently registered on the government application CO-Win – 75 lakh benefits already registered. Followed by those over the age of 50 and population groups under the age of 50, with co-morbidities of about 27 million, will be vaccinated by July. Over 61,000 program managers, 2 lakh vaccinators and 3.7 lakh other members of the vaccination team have been trained so far as part of training at the state, district and bloc levels. The government has not yet placed an official order with the manufacturer COVISHIELD – Serum Institute of India (SII), which has stored 50 million doses for India.
The vaccine flows dry
Given India’s COVID-19 figure, reaching 1.04.31.639 cases and active cases falling to 2.24.190, the nation has deployed the vaccine in section in 700 districts in all states / UTs of India except Uttar Pradesh and Haryana on January 8 the previous land vaccine, a total of 286 meeting locations spread over 125 districts took place on January 2. Both drying trials were successful and aimed at ensuring effective planning and management for the administration of the vaccine in all states and territories of the Union, with Union Health Minister Dr. Harsh Vardhan discussing the Chennai dry run earlier in the day.
Prime Minister Modi will chair all CM meetings on January 11 to discuss the launch of COVID-19 vaccine
DCGI nods to COVISHIELD & COVAXIN
On Sunday, India’s Comptroller General of Drugs (DCGI) VG Somani announced that the Serum Institue of India (Covishield) and Bharat Biotech (Covaxin) vaccines had been granted permission for restricted use in an emergency. Covishield – a recombinant chimpanzee Adenovirus vector vaccine – has an efficacy of 70.42%, with intermediate safety and immunogenicity data from the Phase II / III studies presented in the SEC. 50 million doses were stored.
Meanwhile, Covaxin – a vaccine against the whole virion coronary virus – 22,500 participants were vaccinated in phase III studies and proved to be safe according to the data available so far. On Thursday, Bharat Biotech (BBL) said that the company has completed the registration in phase 3 of the clinical trials of 25,800 participants. According to ICMR, BBL has already given 24,000 volunteers with the first vaccine and 5,000 with the second dose – with no side effects. 20 million doses have been stored and both phase 3 vaccine studies are ongoing.
MP CM clarifies the death of a man 10 days after the COVAXIN trial, considers it a “misconception”
COVAXIN completes enrollment of 25,800 volunteers for phase 3 studies before “dry running”